French biotech TxCell (Euronext Paris: TXCL) has appointed Oliver Danos to its Scientific Advisory Board (SAB).
Dr Danos is senior vice president of cell and gene therapy at US biotech major Biogen (Nasdaq: BIIB) and is seen as a world-leading expert in the field of gene therapy for hematological and neurological diseases.
TxCell, which is focused on developing personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, now has an SAB comprising of four world-leading immunology experts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze